Griffiths Kristi R, Boulet Stephanie, Barakat Sarah, Touyz Stephen, Hay Phillipa, Maguire Sarah, Kohn Michael R
InsideOut Institute, Charles Perkins Centre, University of Sydney, Sydney Local Health District, Sydney, NSW, 2006, Australia.
Brain Dynamics Centre, Westmead Institute for Medical Research, University of Sydney, Westmead, NSW, Australia.
J Eat Disord. 2024 Jun 13;12(1):80. doi: 10.1186/s40337-024-01041-9.
Lisdexamfetamine dimesylate (LDX) has demonstrated safety and efficacy for treatment of Binge Eating Disorder (BED). However, to date, trials have not included participants with co-occurring psychiatric disorders. This study explores how LDX affects eating disorder psychopathology, symptoms of common psychiatric comorbidities of BED (ADHD, depression, anxiety), and psychological quality of life, in people with moderate to severe BED.
These are secondary analyses of an open-label LDX trial conducted in 41 adults (18-40 years) over eight-weeks. Participants received LDX titrated to 50 or 70 mg. Clinical assessments and self-report questionnaires were conducted at baseline and 8-week follow-up.
Eating disorder psychopathology and psychological quality of life improved after 8-weeks of LDX. No significant group-level changes in depression, anxiety or ADHD severity scores were observed. However, the majority within the small subsets with elevated depression and ADHD symptoms experienced reduced depressive and inattentive symptom severity, respectively.
We provide proof-of-concept evidence that LDX may provide broader psychological benefits to individuals with BED, beyond reducing their BE frequency. Effects of LDX on anxiety should be monitored closely by clinicians. Early indications suggest that LDX may be effectively used in people with BED, with and without co-occurring psychiatric conditions, however tolerability may be lower in highly complex cases.
Australian and New Zealand Clinical Trials Registry (anzctr.org.au) #ACTRN12618000623291.
二甲磺酸赖右苯丙胺（LDX）已被证明对治疗暴饮暴食症（BED）具有安全性和有效性。然而，迄今为止，试验尚未纳入同时患有精神疾病的参与者。本研究探讨了LDX如何影响中度至重度BED患者的饮食失调心理病理学、BED常见精神共病（注意力缺陷多动障碍、抑郁症、焦虑症）的症状以及心理生活质量。
这些是对41名18至40岁成年人进行的为期八周的开放标签LDX试验的二次分析。参与者接受滴定至50或70毫克的LDX。在基线和8周随访时进行临床评估和自我报告问卷。
LDX治疗8周后，饮食失调心理病理学和心理生活质量得到改善。未观察到抑郁、焦虑或注意力缺陷多动障碍严重程度评分在组水平上有显著变化。然而，在抑郁和注意力缺陷多动障碍症状升高的小亚组中，大多数人的抑郁和注意力不集中症状严重程度分别有所降低。
我们提供了概念验证证据，表明LDX可能为BED患者带来更广泛的心理益处，而不仅仅是减少他们的暴饮暴食频率。临床医生应密切监测LDX对焦虑的影响。早期迹象表明，LDX可有效用于患有或未患有并发精神疾病的BED患者，然而在高度复杂的病例中耐受性可能较低。
澳大利亚和新西兰临床试验注册中心（anzctr.org.au）#ACTRN12618000623291。
Zotero 插件
